Rexahn Pharmaceuticals, Inc.  

(Public, NYSEMKT:RNN)   Watch this stock  
Find more results for NYSEAMEX:RNN
0.729
-0.010 (-1.41%)
Oct 30 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.72 - 0.75
52 week 0.37 - 1.85
Open 0.75
Vol / Avg. 339,485.00/1.13M
Mkt cap 131.89M
P/E     -
Div/yield     -
EPS -0.12
Shares 178.25M
Beta 1.11
Inst. own 8%
Nov 5, 2014
Rexahn Pharmaceuticals Inc at EBD Group BIO-Europe Conference - 5:00AM EST - Add to calendar
Oct 7, 2014
Rexahn Pharmaceuticals Inc at BIO Investor Forum
Sep 9, 2014
Rexahn Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets 1.94% -55.11%
Return on average equity 2.67% -85.74%
Employees 16 -
CDP Score - -

Address

Suite 455, 15245 Shady Grove Road
ROCKVILLE, MD 20850
United States - Map
+1-240-2685300 (Phone)
+1-240-2685310 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�s pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�s drug candidate, Archexin is an anticancer Akt inhibitor.

Officers and directors

Chang H. Ahn Chairman of the Board, Chief Scientist
Age: 62
Bio & Compensation  - Reuters
Rakesh Soni President, Chief Operating Officer
Age: 58
Bio & Compensation  - Reuters
Peter D. Suzdak Ph.D. Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Tae Heum Jeong Chief Financial Officer, Secretary
Age: 43
Bio & Compensation  - Reuters
Charles G. Beever Independent Director
Age: 61
Bio & Compensation  - Reuters
Peter C. Brandt Independent Director
Age: 57
Bio & Compensation  - Reuters
Mark P. Carthy Independent Director
Age: 53
Bio & Compensation  - Reuters
Kwang Soo Cheong Independent Director
Age: 53
Bio & Compensation  - Reuters
Si Moon Hwang Independent Director
Age: 45
Bio & Compensation  - Reuters